Royal London Asset Management LTD Biomarin Pharmaceutical Inc Transaction History

Royal London Asset Management LTD

$39.4 Billion
Q3 2024

A detailed history of Royal London Asset Management LTD transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Royal London Asset Management LTD holds 77,345 shares of BMRN stock, worth $5.2 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

77,345

Previous 73,287 5.54%

Holding current value

$5.2 Million

Previous $6.03 Million 9.9%

% of portfolio

0.01%

Previous 0.02%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$69.02 - $93.84 $280,083 - $380,802	4,058 Added 5.54%	77,345 $5.44 Million
Q2 2024 Aug 07, 2024	BUY	$74.43 - $92.22 $81,128 - $100,519	1,090 Added 1.51%	73,287 $6.03 Million
Q1 2024 May 14, 2024	SELL	$83.81 - $99.0 $135,772 - $160,380	-1,620 Reduced 2.19%	72,197 $6.31 Million
Q4 2023 Feb 13, 2024	BUY	$76.22 - $98.51 $146,113 - $188,843	1,917 Added 2.67%	73,817 $7.12 Million
Q3 2023 Nov 14, 2023	BUY	$85.07 - $94.48 $308,293 - $342,395	3,624 Added 5.31%	71,900 $6.36 Million
Q2 2023 Aug 11, 2023	BUY	$86.68 - $100.3 $471,885 - $546,033	5,444 Added 8.66%	68,276 $5.92 Million
Q1 2023 May 15, 2023	SELL	$87.74 - $117.27 $93,881 - $125,478	-1,070 Reduced 1.67%	62,832 $6.11 Million
Q3 2022 Nov 14, 2022	SELL	$82.16 - $96.94 $22,758 - $26,852	-277 Reduced 0.43%	63,902 $5.42 Million
Q2 2022 Aug 12, 2022	SELL	$71.48 - $86.85 $8,649 - $10,508	-121 Reduced 0.19%	64,179 $5.32 Million
Q1 2022 May 13, 2022	BUY	$74.28 - $92.69 $267,185 - $333,405	3,597 Added 5.93%	64,300 $4.96 Million
Q4 2021 Oct 18, 2022	SELL	$71.72 - $91.47 $151,974 - $193,824	-2,119 Reduced 3.37%	60,703 $5.37 Million
Q4 2021 Jan 18, 2022	SELL	$71.72 - $91.47 $151,974 - $193,824	-2,119 Reduced 3.37%	60,703 $5.37 Million
Q3 2021 Oct 18, 2022	SELL	$74.77 - $85.47 $155,372 - $177,606	-2,078 Reduced 3.2%	62,822 $4.86 Million
Q3 2021 Nov 02, 2021	SELL	$74.77 - $85.47 $155,372 - $177,606	-2,078 Reduced 3.2%	62,822 $4.86 Million
Q2 2021 Oct 18, 2022	BUY	$75.51 - $84.79 $54,442 - $61,133	721 Added 1.12%	64,900 $5.42 Million
Q1 2021 Oct 17, 2022	BUY	$74.73 - $90.69 $53,880 - $65,387	721 Added 1.12%	64,900 $4.9 Million
Q4 2020 Jan 29, 2021	SELL	$72.61 - $90.2 $26,066 - $32,381	-359 Reduced 0.55%	64,900 $5.69 Million
Q3 2020 Nov 04, 2020	SELL	$71.87 - $131.03 $1,868 - $3,406	-26 Reduced 0.04%	65,259 $4.96 Million
Q2 2020 Jul 31, 2020	SELL	$79.55 - $124.22 $336,178 - $524,953	-4,226 Reduced 6.08%	65,285 $7.98 Million
Q3 2019 Nov 12, 2019	SELL	$67.4 - $85.11 $54,054 - $68,258	-802 Reduced 1.14%	69,511 $4.69 Million
Q1 2019 Apr 30, 2019	SELL	$84.2 - $98.62 $537,111 - $629,096	-6,379 Reduced 8.32%	70,313 $0
Q4 2018 Jan 29, 2019	BUY	$80.14 - $106.07 $388,037 - $513,590	4,842 Added 6.74%	76,692 $6.41 Million
Q3 2018 Nov 08, 2018	SELL	$93.92 - $105.72 $31,557 - $35,521	-336 Reduced 0.47%	71,850 $0
Q2 2018 Sep 19, 2018	BUY	$76.01 - $99.03 $5.49 Million - $7.15 Million	72,186 New	72,186 $6.8 Million

Others Institutions Holding BMRN

# of Institutions

638

Shares Held

178M

Call Options Held

2.01M

Put Options Held

1.28M

View Full List

About BIOMARIN PHARMACEUTICAL INC

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.5B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

More about BMRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal London Asset Management LTD, based on Form 13F filings with the SEC.

News

Stay updated on Royal London Asset Management LTD with notifications on news.

Account

Royal London Asset Management LTD Biomarin Pharmaceutical Inc Transaction History